|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Certificates of deposit | ||||||||||||||||||||
| Securities available for sale, at fair value | ||||||||||||||||||||
| Federal Home Loan Bank of Boston stock, at cost | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Less allowance for loan losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Operating lease, right-of-use asset | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Net deferred tax asset | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term borrowings | ||||||||||||||||||||
| Subordinated debt | ||||||||||||||||||||
| Lease liability | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $0.01 par value; 1,000,000 shares authorized, none issued | ||||||||||||||||||||
| Common stock, $0.01 par value; 14,000,000 shares authorized, 2,608,872 and 2,599,105 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Unearned compensation - ESOP | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
